Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Broad, AstraZeneca Target Antibiotics
by Lisa M. Jarvis
September 17, 2012
| A version of this story appeared in
Volume 90, Issue 38
AstraZeneca and the Broad Institute will work together to find new antibacterial and antiviral compounds. Under the two-year pact, Broad will screen its custom-made chemical library of 100,000 molecules generated by diversity-oriented synthesis. AstraZeneca will be responsible for optimizing and developing any lead compounds discovered by Broad. In the past 30 years, just two new classes of antibiotics have emerged, despite an alarming rise in drug-resistant bacteria, AstraZeneca notes.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter